-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Reiterates Buy on Opus Genetics, Maintains $12 Price Target

Benzinga·07/06/2026 16:54:30
Listen to the news
BTIG analyst Thomas Shrader reiterates Opus Genetics (NASDAQ:IRD) with a Buy and maintains $12 price target.